{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T23:08:28Z","timestamp":1793920108661,"version":"4.8.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T00:00:00Z","timestamp":1688428800000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100004593","name":"Universidad Aut\u00f3noma de Madrid","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004593","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s40261-023-01280-9","type":"journal-article","created":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T13:02:29Z","timestamp":1688994149000},"page":"517-527","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Real-world Performance of a New Strategy for Off-Label Use of Guselkumab in Moderate to Severe Psoriasis: Super-Responder Patients as the Epitome of Efficacy and Optimisation"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9840-6628","authenticated-orcid":false,"given":"Pedro","family":"Herranz-Pinto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Luisa","family":"Alonso-Pacheco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Feltes-Ochoa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ander","family":"Mayor-Ibarguren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Servera-Negre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Manuel","family":"Busto-Leis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Angeles","family":"Gonzalez-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Herrero-Ambrosio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,4]]},"reference":[{"key":"1280_CR1","doi-asserted-by":"publisher","first-page":"m1590","DOI":"10.1136\/bmj.m1590","volume":"369","author":"R Parisi","year":"2020","unstructured":"Parisi R, Iskandar IYK, Kontopantelis E, Augustin M, Griffiths CEM, Ashcroft DM, Global Psoriasis Atlas. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020;369:m1590. https:\/\/doi.org\/10.1136\/bmj.m1590.","journal-title":"BMJ"},{"issue":"1","key":"1280_CR2","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.jaad.2019.09.071","volume":"82","author":"SR Feldman","year":"2020","unstructured":"Feldman SR. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 2020;82(1):256\u20137. https:\/\/doi.org\/10.1016\/j.jaad.2019.09.071.","journal-title":"J Am Acad Dermatol"},{"key":"1280_CR3","doi-asserted-by":"publisher","first-page":"247","DOI":"10.2147\/BTT.S267428","volume":"15","author":"F Bellinato","year":"2021","unstructured":"Bellinato F, Gisondi P, Girolomoni G. Latest advances for the treatment of chronic plaque psoriasis with biologics and oral small molecules. Biologics. 2021;15:247\u201353. https:\/\/doi.org\/10.2147\/BTT.S267428.","journal-title":"Biologics"},{"issue":"13","key":"1280_CR4","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1007\/s40265-017-0805-4","volume":"77","author":"A Markham","year":"2017","unstructured":"Markham A. Guselkumab: first global approval. Drugs. 2017;77(13):1487\u201392. https:\/\/doi.org\/10.1007\/s40265-017-0805-4.","journal-title":"Drugs"},{"issue":"3","key":"1280_CR5","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","volume":"76","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, Papp KA, Griffiths CEM, Randazzo B, Wasfi Y, Shen YK, Li S, Kimball AB. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76(3):405\u201317. https:\/\/doi.org\/10.1016\/j.jaad.2016.11.041.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1280_CR6","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","volume":"76","author":"K Reich","year":"2017","unstructured":"Reich K, Armstrong AW, Foley P, Song M, Wasfi Y, Randazzo B, Li S, Shen YK, Gordon KB. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76(3):418\u201331. https:\/\/doi.org\/10.1016\/j.jaad.2016.11.042.","journal-title":"J Am Acad Dermatol"},{"issue":"10230","key":"1280_CR7","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S0140-6736(20)30265-8","volume":"395","author":"A Deodhar","year":"2020","unstructured":"Deodhar A, Helliwell PS, Boehncke WH, Kollmeier AP, Hsia EC, Subramanian RA, Xu XL, Sheng S, Agarwal P, Zhou B, Zhuang Y, Ritchlin CT, DISCOVER-1 Study Group. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNF\u03b1 inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395(10230):1115\u201325. https:\/\/doi.org\/10.1016\/S0140-6736(20)30265-8.","journal-title":"Lancet"},{"issue":"10230","key":"1280_CR8","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/S0140-6736(20)30265-8","volume":"395","author":"PJ Mease","year":"2020","unstructured":"Mease PJ, Rahman P, Gottlieb AB, Kollmeier AP, Hsia EC, Xu XL, Sheng S, Agarwal P, Zhou B, Zhuang Y, van der Heijde D, McInnes IB, DISCOVER-2 Study Group. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395(10230):1126\u201336. https:\/\/doi.org\/10.1016\/S0140-6736(20)30265-8.","journal-title":"Lancet"},{"key":"1280_CR9","unstructured":"tremfya-epar-product-information_en.pdf [Internet]. [cited November 30, 2022]. Accessed date 2 nov 2022 https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tremfya-epar-product-information_en.pdf."},{"key":"1280_CR10","unstructured":"Augustin M, Jazra M, \u00d6zt\u00fcrk B. Long-term drug survival over 5 years of continuous guselkumab treatment in patients with moderate-to-severe psoriasis: a post hoc analysis of the vOYAGE 1. In: Poster at 6th World Psoriasis & Psoriatic Arthritis Conference. 2021."},{"issue":"4","key":"1280_CR11","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/j.jaad.2019.10.018","volume":"82","author":"K Reich","year":"2020","unstructured":"Reich K, Griffiths CEM, Gordon KB, Papp KA, Song M, Randazzo B, Li S, Shen YK, Han C, Kimball AB, Armstrong AW, Foley P, Blauvelt A. Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials. J Am Acad Dermatol. 2020;82(4):936\u201345. https:\/\/doi.org\/10.1016\/j.jaad.2019.10.018.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1280_CR12","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1111\/bjd.17438","volume":"180","author":"K Reich","year":"2019","unstructured":"Reich K, Papp KA, Armstrong AW, Wasfi Y, Li S, Shen YK, Randazzo B, Song M, Kimball AB. Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studies. Br J Dermatol. 2019;180(5):1039\u201349. https:\/\/doi.org\/10.1111\/bjd.17438.","journal-title":"Br J Dermatol"},{"issue":"6","key":"1280_CR13","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1111\/bjd.20351","volume":"185","author":"K Reich","year":"2021","unstructured":"Reich K, Gordon KB, Strober BE, Armstrong AW, Miller M, Shen YK, You Y, Han C, Yang YW, Foley P, Griffiths CEM. Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2. Br J Dermatol. 2021;185(6):1146\u201359. https:\/\/doi.org\/10.1111\/bjd.20351.","journal-title":"Br J Dermatol"},{"issue":"10201","key":"1280_CR14","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/S0140-6736(19)31781-2","volume":"394","author":"K Reich","year":"2019","unstructured":"Reich K, Armstrong AW, Langley RG, Flavin S, Randazzo B, Li S, Hsu MC, Branigan P, Blauvelt A. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Lancet. 2019;394(10201):831\u20139. https:\/\/doi.org\/10.1016\/S0140-6736(19)31781-2.","journal-title":"Lancet"},{"issue":"9","key":"1280_CR15","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1111\/jdv.17852","volume":"36","author":"S Gerdes","year":"2022","unstructured":"Gerdes S, Asadullah K, Hoffmann M, Korge B, Mortazawi D, Wegner S, Personke Y, Gomez M, Sticherling M. Real-world evidence from the non-interventional, prospective, German multicentre PERSIST study of patients with psoriasis after 1 year of treatment with guselkumab. J Eur Acad Dermatol Venereol. 2022;36(9):1568\u201377. https:\/\/doi.org\/10.1111\/jdv.17852.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1280_CR16","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jdin.2021.09.007","volume":"4","author":"PD Ghislain","year":"2021","unstructured":"Ghislain PD, Failla V, Lambert J, Soenen R, Grine L, Tannous J, Guiot F, Willaert F, Fierens H, Vandaele M, Boonen H, Saerens J, Meuleman V, Stockman A, Belpaire A, Swimberghe S, Temmerman L, Dekeyser S, Lambert JM, de Schaetzen V, de la Brassinne M, Benhadou F. Effectiveness and tolerability of guselkumab in patients with psoriasis: a longitudinal Belgian retrospective multicenter study. JAAD Int. 2021;4:15\u20137. https:\/\/doi.org\/10.1016\/j.jdin.2021.09.007.","journal-title":"JAAD Int."},{"issue":"2","key":"1280_CR17","doi-asserted-by":"publisher","first-page":"e14798","DOI":"10.1111\/dth.14798","volume":"34","author":"R Ruiz-Villaverde","year":"2021","unstructured":"Ruiz-Villaverde R, Rodriguez-Fernandez-Freire L, Armario-Hita JC, P\u00e9rez-Gil A, Gal\u00e1n-Guti\u00e9rrez M. Guselkumab: mid-term effectiveness, drug survival, and safety in real clinical practice. Dermatol Ther. 2021;34(2):e14798. https:\/\/doi.org\/10.1111\/dth.14798.","journal-title":"Dermatol Ther"},{"issue":"2","key":"1280_CR18","doi-asserted-by":"publisher","first-page":"e15231","DOI":"10.1111\/dth.15231","volume":"35","author":"E Del Alc\u00e1zar","year":"2022","unstructured":"Del Alc\u00e1zar E, L\u00f3pez-Ferrer A, Mart\u00ednez-Dom\u00e9nech \u00c1, Ruiz-Villaverde R, Llamas-Velasco MDM, Rocamora V, Juli\u00e0 M, Notario J, Fern\u00e1ndez-Freire LR, Sahuquillo-Torralba A, Vidal D, Rivera R, Carretero G, Mateu A, de la Cueva P, Carrascosa JM. Effectiveness and safety of guselkumab for the treatment of psoriasis in real-world settings at 24 weeks: a retrospective, observational, multicentre study by the Spanish Psoriasis Group. Dermatol Ther. 2022;35(2):e15231. https:\/\/doi.org\/10.1111\/dth.15231.","journal-title":"Dermatol Ther"},{"issue":"4","key":"1280_CR19","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1080\/09546634.2021.1973847","volume":"33","author":"P Dapavo","year":"2022","unstructured":"Dapavo P, Siliquini N, Mastorino L, Avallone G, Merli M, Agostini A, Cariti C, Viola R, Stroppiana E, Verrone A, Ortoncelli M, Quaglino P, Ribero S. Efficacy, safety, and drug survival of IL-23, IL-17, and TNF-alpha inhibitors for psoriasis treatment: a retrospective study. J Dermatolog Treat. 2022;33(4):2352\u20137. https:\/\/doi.org\/10.1080\/09546634.2021.1973847.","journal-title":"J Dermatolog Treat"},{"issue":"4","key":"1280_CR20","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s40257-021-00601-1","volume":"22","author":"T Torres","year":"2021","unstructured":"Torres T, Puig L, Vender R, Lynde C, Piaserico S, Carrascosa JM, Gisondi P, Daud\u00e9n E, Conrad C, Mendes-Bastos P, Ferreira P, Leite L, Lu JD, Valerio J, Bruni M, Messina F, Nidegger A, Llamas-Velasco M, Del Alcazar E, Mufti A, White K, Caldarola G, Teixeira L, Romanelli P, Desai K, Gkalpakiotis S, Romanelli M, Yeung J, Nogueira M, Chiricozzi A. Drug survival of IL-12\/23, IL-17 and IL-23 inhibitors for psoriasis treatment: a retrospective multi-country, multicentric cohort study. Am J Clin Dermatol. 2021;22(4):567\u201379. https:\/\/doi.org\/10.1007\/s40257-021-00601-1.","journal-title":"Am J Clin Dermatol"},{"issue":"8","key":"1280_CR21","doi-asserted-by":"publisher","first-page":"864","DOI":"10.36849\/JDD.6962","volume":"21","author":"D Marletta","year":"2021","unstructured":"Marletta D, Murgia G, Cattaneo A, Carrera C, Marzano A. Single-centre real-life experience of guselkumab in patients with moderate-to-severe plaque psoriasis. J Drugs Dermatol JDD. 2021;21(8):864\u20136. https:\/\/doi.org\/10.36849\/JDD.6962.","journal-title":"J Drugs Dermatol JDD"},{"issue":"6","key":"1280_CR22","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.1080\/09546634.2022.2081655","volume":"33","author":"M Megna","year":"2022","unstructured":"Megna M, Tommasino N, Potestio L, Battista T, Ruggiero A, Noto M, Fabbrocini G, Genco L. Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an italian 28-week retrospective study. J Dermatolog Treat. 2022;33(6):2813\u201320. https:\/\/doi.org\/10.1080\/09546634.2022.2081655.","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"1280_CR23","doi-asserted-by":"publisher","first-page":"e15214","DOI":"10.1111\/dth.15214","volume":"35","author":"A Ruggiero","year":"2022","unstructured":"Ruggiero A, Fabbrocini G, Cinelli E, Megna M. Real-world practice indirect comparison between guselkumab and risankizumab: results from an Italian Retrospective Study. Dermatol Ther. 2022;35(1):e15214. https:\/\/doi.org\/10.1111\/dth.15214.","journal-title":"Dermatol Ther"},{"issue":"6","key":"1280_CR24","doi-asserted-by":"publisher","first-page":"e13964","DOI":"10.1111\/dth.13964","volume":"33","author":"I Snast","year":"2020","unstructured":"Snast I, Sherman S, Holzman R, Hodak E, Pavlovsky L. Real-life experience of guselkumab in patients with psoriasis. Dermatol Ther. 2020;33(6):e13964. https:\/\/doi.org\/10.1111\/dth.13964.","journal-title":"Dermatol Ther"},{"issue":"4","key":"1280_CR25","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s40257-021-00686-8","volume":"23","author":"M Masson Regnault","year":"2022","unstructured":"Masson Regnault M, Shourick J, Jendoubi F, Tauber M, Paul C. Time to relapse after discontinuing systemic treatment for psoriasis: a systematic review. Am J Clin Dermatol. 2022;23(4):433\u201347. https:\/\/doi.org\/10.1007\/s40257-021-00686-8.","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"1280_CR26","doi-asserted-by":"publisher","first-page":"e65","DOI":"10.1111\/jdv.16870","volume":"35","author":"R Rivera","year":"2021","unstructured":"Rivera R, Martorell A, L\u00f3pez A, Salgado L, Sahuquillo A, de la Cueva P, Herranz P, Rat\u00f3n JA, Ferr\u00e1n M, Izu R, Ruiz-Genao D, Garc\u00eda-Donoso C, Carrascosa JM. Maintenance of response following discontinuation of guselkumab and secukinumab in Spanish patients who participated in the ECLIPSE study. J Eur Acad Dermatol Venereol. 2021;35(1):e65\u20137. https:\/\/doi.org\/10.1111\/jdv.16870.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"1280_CR27","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1001\/jamadermatol.2020.0723","volume":"156","author":"A Blauvelt","year":"2020","unstructured":"Blauvelt A, Leonardi CL, Gooderham M, Papp KA, Philipp S, Wu JJ, Igarashi A, Flack M, Geng Z, Wu T, Camez A, Williams D, Langley RG. Efficacy and safety of continuous risankizumab therapy vs treatment withdrawal in patients with moderate to severe plaque psoriasis: a phase 3 randomized clinical trial. JAMA Dermatol. 2020;156(6):649\u201358. https:\/\/doi.org\/10.1001\/jamadermatol.2020.0723.","journal-title":"JAMA Dermatol"},{"issue":"4","key":"1280_CR28","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1111\/jdv.16964","volume":"35","author":"RB Warren","year":"2021","unstructured":"Warren RB, Carrascosa JM, Fumero E, Schoenenberger A, Lebwohl MG, Szepietowski JC, Reich K. Time to relapse after tildrakizumab withdrawal in patients with moderate-to-severe psoriasis who were responders at week 28: Post hoc analysis through 64 weeks from reSURFACE 1 trial. JEADV. 2021;35(4):919\u201327. https:\/\/doi.org\/10.1111\/jdv.16964.","journal-title":"JEADV."},{"issue":"4","key":"1280_CR29","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1080\/09546634.2019.1646783","volume":"31","author":"R Sanz-Gil","year":"2020","unstructured":"Sanz-Gil R, Pellicer A, Montesinos MC, Valcuende-Cavero F. Improved effectiveness from individualized dosing of self-administered biologics for the treatment of moderate-to-severe psoriasis: a 5-year retrospective chart review from a Spanish University Hospital. J Dermatolog Treat. 2020;31(4):370\u20137. https:\/\/doi.org\/10.1080\/09546634.2019.1646783.","journal-title":"J Dermatolog Treat"},{"issue":"4","key":"1280_CR30","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1007\/s13555-021-00608-1","volume":"11","author":"A Gambardella","year":"2021","unstructured":"Gambardella A, Licata G, Sohrt A. Dose adjustment of biologic treatments for moderate-to-severe plaque psoriasis in the real world: a systematic review. Dermatol Ther (Heidelb). 2021;11(4):1141\u201356. https:\/\/doi.org\/10.1007\/s13555-021-00608-1.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"6","key":"1280_CR31","doi-asserted-by":"publisher","first-page":"502","DOI":"10.3109\/09546634.2014.999550","volume":"26","author":"JM Carrascosa","year":"2015","unstructured":"Carrascosa JM, Garcia-Doval I, P\u00e9rez-Zafrilla B, Carretero G, Vanaclocha F, Daud\u00e9n E, De la Cueva-Dobao P, Belinch\u00f3n I, Alsina M, L\u00f3pez-Estebaranz JL, Ferr\u00e1n M, Torrado R, Rivera R, Carazo C, Barboza L, Ferr\u00e1ndiz C, BIOBADADERM Study Group. Use of off-label doses is frequent in biologic therapy for moderate to severe psoriasis: a cross-sectional study in clinical practice. J Dermatolog Treat. 2015;26(6):502\u20136. https:\/\/doi.org\/10.3109\/09546634.2014.999550.","journal-title":"J Dermatolog Treat"},{"issue":"9","key":"1280_CR32","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jcad.2021.07.012","volume":"14","author":"KJ Tan","year":"2021","unstructured":"Tan KJ, Noliza Encarnacion MR, Marushchak O, Anvekar R. Management of psoriasis during the coronavirus disease 2019 pandemic. J Clin Aesthet Dermatol. 2021;14(9):41\u20134. https:\/\/doi.org\/10.1016\/j.jcad.2021.07.012.","journal-title":"J Clin Aesthet Dermatol."},{"issue":"12","key":"1280_CR33","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1016\/j.jid.2019.06.143","volume":"139","author":"KB Gordon","year":"2019","unstructured":"Gordon KB, Armstrong AW, Foley P, Song M, Shen YK, Li S, Mu\u00f1oz-El\u00edas EJ, Branigan P, Liu X, Reich K. Guselkumab efficacy after withdrawal is associated with suppression of serum IL-23-regulated IL-17 and IL-22 in psoriasis: VOYAGE 2 Study. J Invest Dermatol. 2019;139(12):2437-2446.e1. https:\/\/doi.org\/10.1016\/j.jid.2019.06.143.","journal-title":"J Invest Dermatol"},{"issue":"3","key":"1280_CR34","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.ad.2022.01.001","volume":"113","author":"JM Carrascosa","year":"2022","unstructured":"Carrascosa JM, Puig L, Belinch\u00f3n Romero I, Salgado-Boquete L, del Alc\u00e1zar E, Andr\u00e9s Lencina JJ, Moreno D, de la Cueva P. Actualizaci\u00f3n pr\u00e1ctica de las recomendaciones del Grupo de Psoriasis de la Academia Espa\u00f1ola de Dermatolog\u00eda y Venereolog\u00eda (GPS) para el tratamiento de la psoriasis con terapia biol\u00f3gica. Parte 1. \u00abConceptos y manejo general de la psoriasis con terapia biol\u00f3gica\u00bb. Actas Dermosifiliogr. 2022;113(3):261\u201377. https:\/\/doi.org\/10.1016\/j.ad.2022.01.001.","journal-title":"Actas Dermosifiliogr"},{"issue":"6","key":"1280_CR35","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.ad.2022.03.002","volume":"113","author":"JM Carrascosa","year":"2022","unstructured":"Carrascosa JM, Puig L, Romero IB, Salgado-Boquete L, del Alc\u00e1zar E, Lencina JJA, Moreno D, de la Cueva P. Actualizaci\u00f3n pr\u00e1ctica de las recomendaciones del Grupo de Psoriasis de la Academia Espa\u00f1ola de Dermatolog\u00eda y Venereolog\u00eda (GPS) para el tratamiento de la psoriasis con terapia biol\u00f3gica. Parte 2 \u00abManejo de poblaciones especiales, pacientes con comorbilidad y gesti\u00f3n del riesgo\u00bb. Actas Dermosifiliogr. 2022;113(6):583\u2013609. https:\/\/doi.org\/10.1016\/j.ad.2022.03.002.","journal-title":"Actas Dermosifiliogr"},{"issue":"8","key":"1280_CR36","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1080\/09546634.2018.1451989","volume":"29","author":"RM Romero-Jimenez","year":"2018","unstructured":"Romero-Jimenez RM, Escudero-Vilaplana V, Baniandres Rodriguez O, Garc\u00eda Mart\u00edn E, Mateos Mayo A, Sanjurjo SM. Association between clinical factors and dose modification strategies in the treatment with ustekinumab for moderate-to-severe plaque psoriasis. J Dermatolog Treat. 2018;29(8):792\u20136. https:\/\/doi.org\/10.1080\/09546634.2018.1451989.","journal-title":"J Dermatolog Treat"},{"issue":"9","key":"1280_CR37","doi-asserted-by":"publisher","first-page":"e049822","DOI":"10.1136\/bmjopen-2021-049822","volume":"11","author":"K Eyerich","year":"2021","unstructured":"Eyerich K, Weisenseel P, Pinter A, Sch\u00e4kel K, Asadullah K, Wegner S, Mu\u00f1oz-Elias EJ, Bartz H, Taut FJH, Reich K. IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE). BMJ Open. 2021;11(9):e049822. https:\/\/doi.org\/10.1136\/bmjopen-2021-049822.","journal-title":"BMJ Open"},{"key":"1280_CR38","unstructured":"Knut S, Khusru A, Andreas P. Prolonged q16w treatment interval of guselkumab is non-inferior to q8w dosing for maintaining disease control in super responders: primary results from GUIDE at Week 68 in patients with psoriasis. In: Poster Presented at the ESDR; Sep 2022."},{"key":"1280_CR39","unstructured":"Schaekel K. Early disease intervention in psoriasis leads to a faster and higher rate of complete skin clearance: week 28 results from the GUIDE study. In: Proceedings of the ISDS Conference. 2021; New York, NY, USA."},{"key":"1280_CR40","doi-asserted-by":"crossref","unstructured":"Sch\u00e4kel K. Prognostic factors for early PASI 100 response in psoriasis patients treated with guselkumab: Results from the GUIDE study. In: Poster Presented at the AAD; March 2022.","DOI":"10.1016\/j.jaad.2022.06.813"},{"issue":"2","key":"1280_CR41","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1111\/bjd.18143","volume":"182","author":"K Reich","year":"2020","unstructured":"Reich K, Blauvelt A, Tsai TF, Tyring S, Vanaclocha F, Kingo K, et al. Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE study. Br J Dermatol. 2020;182(2):426\u201334. https:\/\/doi.org\/10.1111\/bjd.18143.","journal-title":"Br J Dermatol"},{"issue":"7","key":"1280_CR42","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1016\/j.jid.2020.12.012","volume":"141","author":"H Mehta","year":"2021","unstructured":"Mehta H, Mashiko S, Angsana J, Rubio M, Hsieh YCM, Maari C, et al. Differential changes in inflammatory mononuclear phagocyte and T-cell profiles within psoriatic skin during treatment with guselkumab vs. secukinumab. J Invest Dermatol. 2021;141(7):1707-1718.e9. https:\/\/doi.org\/10.1016\/j.jid.2020.12.012.","journal-title":"J Invest Dermatol"},{"issue":"11","key":"1280_CR43","doi-asserted-by":"publisher","first-page":"e15835","DOI":"10.1111\/dth.15835","volume":"35","author":"R Ruiz-Villaverde","year":"2022","unstructured":"Ruiz-Villaverde R, Chinchay FV, Rodriguez-Fernandez-Freire L, Armario-Hita JC, P\u00e9rez-Gil A, Gal\u00e1n-Guti\u00e9rrez M. Guselkumab dosing interval optimization in adult patients with moderate-to-severe psoriasis switching from ustekinumab. Dermatol Ther. 2022;35(11):e15835. https:\/\/doi.org\/10.1111\/dth.15835.","journal-title":"Dermatol Ther"},{"issue":"10","key":"1280_CR44","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1001\/jamadermatol.2022.2269","volume":"158","author":"ZZN Yiu","year":"2022","unstructured":"Yiu ZZN, Becher G, Kirby B, Laws P, Reynolds NJ, Smith CH, Warren RB, Griffiths CEM, BADBIR Study Group. Drug survival associated with effectiveness and safety of treatment with guselkumab, ixekizumab, secukinumab, ustekinumab, and adalimumab in patients with psoriasis. JAMA Dermatol. 2022;158(10):1131\u201341. https:\/\/doi.org\/10.1001\/jamadermatol.2022.2269.","journal-title":"JAMA Dermatol"},{"key":"1280_CR45","doi-asserted-by":"publisher","first-page":"151979","DOI":"10.1016\/j.semarthrit.2022.03.018","volume":"53","author":"A Egeberg","year":"2022","unstructured":"Egeberg A, Rosen\u00f8 NAL, Aagaard D, L\u00f8rup EH, Nielsen ML, Nymand L, Kristensen LE, Thyssen JP, Thomsen SF, Cordtz RL, Loft N, Skov L, Bryld LE, Rasmussen MK, H\u00f8jgaard P, Kristensen S, Dreyer L. Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis\u2014a nationwide cohort study from the DANBIO and DERMBIO registries. Semin Arthritis Rheum. 2022;53:151979. https:\/\/doi.org\/10.1016\/j.semarthrit.2022.03.018.","journal-title":"Semin Arthritis Rheum"},{"key":"1280_CR46","doi-asserted-by":"publisher","first-page":"adv00631","DOI":"10.2340\/actadv.v101.910","volume":"102","author":"T M\u00e4lk\u00f6nen","year":"2022","unstructured":"M\u00e4lk\u00f6nen T, Nuutinen P, Hallinen T, Soini E, Nissinen R, Wennerst\u00f6m C, Rantanen T, Hagman JH, Harvima R, H\u00f6\u00f6k-Nikanne J, Ilves T, Lintu P, Malanin K, Soram\u00e4ki I, Tasanen K, Teho A, V\u00e4h\u00e4vihu K, It\u00e4linna S, Leinonen P, Saraj\u00e4rvi P, Huilaja L, Pasternack R. Guselkumab treatment outcomes and persistence in a nationwide real-world cohort of patients with plaque psoriasis. Acta Derm Venereol. 2022;102:adv00631. https:\/\/doi.org\/10.2340\/actadv.v101.910.","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"1280_CR47","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1007\/s13555-021-00618-w","volume":"11","author":"E Daud\u00e9n","year":"2021","unstructured":"Daud\u00e9n E, de Lima GPG, Armesto S, Herrera-Acosta E, Vidal D, Villarasa E, Rivera R, de la Cueva P, Martorell A, Ballesca F, Belinch\u00f3n I, Carretero G, Rodr\u00edguez L, Romero-Mat\u00e9 A, Pujol-Montcus\u00ed J, Salgado L, Sahuquillo-Torralba A, Coto-Segura P, Baniandr\u00e9s O, Feltes R, Alsina M, Llamas-Velasco M. Multicenter retrospective study of secukinumab drug survival in psoriasis patients in a daily practice setting: a long-term experience in Spain. Dermatol Ther (Heidelb). 2021;11(6):2207\u201315. https:\/\/doi.org\/10.1007\/s13555-021-00618-w.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"10","key":"1280_CR48","doi-asserted-by":"publisher","first-page":"e364","DOI":"10.1111\/jdv.15862","volume":"33","author":"M Talamonti","year":"2019","unstructured":"Talamonti M, D\u2019Adamio S, Galluccio T, Andreani M, Pastorino R, Egan CG, Bianchi L, Galluzzo M. High-resolution HLA typing identifies a new \u00absuper responder\u00bb subgroup of HLA-C06:02-positive psoriatic patients: HLA-C06:02\/HLA-C*04, in response to ustekinumab. J Eur Acad Dermatol Venereol. 2019;33(10):e364\u20137. https:\/\/doi.org\/10.1111\/jdv.15862.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"1280_CR49","doi-asserted-by":"publisher","first-page":"AB1145","DOI":"10.1016\/j.jaad.2020.09.1179","volume":"83","author":"K Reich","year":"2020","unstructured":"Reich K, Strober B, Langley R, Song M, Shen YK, You Y, Foley P, Blauvelt A. Characterization of super responders to guselkumab treatment in moderate to severe psoriasis: results from the VOYAGE 1 and 2 clinical trials. J Am Acad Dermatol. 2020;83(6):AB1145. https:\/\/doi.org\/10.1016\/j.jaad.2020.09.1179.","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"1280_CR50","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1111\/ijd.15819","volume":"61","author":"R Ruiz-Villaverde","year":"2022","unstructured":"Ruiz-Villaverde R, Rodriguez-Fernandez-Freire L, Armario-Hita JC, P\u00e9rez-Gil A, Gal\u00e1n-Guti\u00e9rrez M. Super responders to guselkumab treatment in moderate-to-severe psoriasis: a real clinical practice pilot series. Int J Dermatol. 2022;61(8):1029\u201333. https:\/\/doi.org\/10.1111\/ijd.15819.","journal-title":"Int J Dermatol"},{"issue":"9","key":"1280_CR51","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.3390\/life12090141","volume":"12","author":"R Ruiz-Villaverde","year":"2022","unstructured":"Ruiz-Villaverde R, Vasquez-Chinchay F, Rodriguez-Fernandez-Freire L, Armario-Hita JC, P\u00e9rez-Gil A, Gal\u00e1n-Guti\u00e9rrez M. Super-responders in moderate-severe psoriasis under guselkumab treatment: myths, realities and future perspectives. Life (Basel). 2022;12(9):1412. https:\/\/doi.org\/10.3390\/life12090141.","journal-title":"Life (Basel)."},{"issue":"8","key":"1280_CR52","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1111\/jdv.17913","volume":"36","author":"N Loft","year":"2022","unstructured":"Loft N, Egeberg A, Rasmussen MK, Bryld LE, Nissen CV, Dam TN, Ajgeiy KK, Iversen L, Skov L. Prevalence and characterization of treatment-refractory psoriasis and super-responders to biologic treatment: a nationwide study. J Eur Acad Dermatol Venereol. 2022;36(8):1284\u201391. https:\/\/doi.org\/10.1111\/jdv.17913.","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-023-01280-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-023-01280-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-023-01280-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T12:03:04Z","timestamp":1695297784000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-023-01280-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":52,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["1280"],"URL":"https:\/\/doi.org\/10.1007\/s40261-023-01280-9","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"29 May 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. No sources of funding were used to conduct this study or prepare this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Pedro Herranz-Pinto has received honoraria for acting as a consultant and\/or speaker and\/or investigator for AbbVie, Almirall, Amgen, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Janssen, LEO Pharma, Eli Lilly, Novartis, Pfizer, Sanofi and UCB Pharma. Rosa Feltes-Ochoa has received honoraria for acting as a consultant and\/or speaker and\/or investigator for AbbVie, Almirall, Amgen, Celgene, Janssen, LEO Pharma, Sanofi and Novartis. Ander Mayor-Ibarguren has received honoraria for acting as a consultant and\/or speaker and\/or investigator for AbbVie, Almirall, Amgen, Janssen, LEO Pharma, Eli Lilly and Novartis. Maria Luisa Alonso-Pacheco has received honoraria for acting as a consultant and\/or speaker and\/or investigator for AbbVie, Almirall, Amgen, Biogen, Celgene, Janssen, LEO Pharma, Eli Lilly, and Novartis. Guillermo Servera-Negre, Jose Manuel Busto-Leis, Maria Angeles Gonzalez-Fern\u00e1ndez and Alicia Herrero-Ambrosio declare no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Not applicable","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Materials"}},{"value":"The present study was conducted in accordance with the Declaration of Helsinki (initially published in 1964) on Ethical Principles for Medical Research Involving Human Subjects and after approval by the local ethical committees.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Informed consent was waived due to the study\u2019s retrospective design. Data were properly anonymised before the analysis.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"All authors participated in data collection and interpretation of the data, provided critical feedback on the manuscript, approved the final manuscript for submission, and were accountable for the accuracy and integrity of the article.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}